Europe Conjugate Vaccine Market (2018-2023)
The report is sent in 5-10 business days after order is placed.
Europe Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. Europe is a market with stable growth for conjugate vaccines. The conjugate vaccine market in Europe is expected to expand at a CAGR of 3.6% leading to a revenue of USD 8.94 Bn by 2023. By volume, it is anticipated to reach 504.46 Million units by 2023, expanding at a CAGR of 3.7%.
The U.K. was the first country to introduce MenB-4C into their National Infant Immunization Program (2015). In all EU/EEA countries, Hib vaccination has been part of the immunization programs, since 2010, and high coverage has been sustained.
Market Segmentation:
Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others.
Based on end user, the market is segmented into pediatric and adult.
Based on countries, the Europe market is divided into EU5 and Rest of EU.
Key growth factors:
The European market will not display any extraordinary growth but average figures. Key growth factors include increasing emphasis on and availability of funds for research and development. Moreover, advancements in medical science, awareness about the availability of a higher number of vaccines for diseases will drive the growth of this market. Increasing vaccination programs by government, their initiatives, and increase in research and development activities will result in the growth of this market.
Threats and key players:
The Europe conjugate vaccine market is expected to grow at a steady pace. The scope for significant growth is limited. Vaccine shortages are a major problem which will hinder the growth of the market. The shortage of vaccines affecting some EU/EEA Member States had direct effects on the delivery of national vaccination programmes. Since 2015, nine EU/EEA member states had to adjust their immunization policies.
Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.
What’s covered in the report?
1. Overview of the Europe conjugate vaccine market
2. Market drivers and challenges in the Europe conjugate vaccine market
3. Market trends in the Europe conjugate vaccine market
4. Historical, current and forecasted market size data for Europe based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for Europe based on end user (pediatric and adult conjugate vaccines) – by revenue and by volume
6. Historical, current and forecasted market size data of conjugate vaccines based on countries (EU5, Rest of EU) – by revenue and by volume
7. Historical, current and forecasted market size data for country-wise segments – by revenue and by volume
8. Analysis of the competitive landscape and profiles of major companies operating in the European market
Why buy?
With the given market data, Netscribes offers customizations according to specific needs.
Europe Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. Europe is a market with stable growth for conjugate vaccines. The conjugate vaccine market in Europe is expected to expand at a CAGR of 3.6% leading to a revenue of USD 8.94 Bn by 2023. By volume, it is anticipated to reach 504.46 Million units by 2023, expanding at a CAGR of 3.7%.
The U.K. was the first country to introduce MenB-4C into their National Infant Immunization Program (2015). In all EU/EEA countries, Hib vaccination has been part of the immunization programs, since 2010, and high coverage has been sustained.
Market Segmentation:
Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others.
Based on end user, the market is segmented into pediatric and adult.
Based on countries, the Europe market is divided into EU5 and Rest of EU.
Key growth factors:
The European market will not display any extraordinary growth but average figures. Key growth factors include increasing emphasis on and availability of funds for research and development. Moreover, advancements in medical science, awareness about the availability of a higher number of vaccines for diseases will drive the growth of this market. Increasing vaccination programs by government, their initiatives, and increase in research and development activities will result in the growth of this market.
Threats and key players:
The Europe conjugate vaccine market is expected to grow at a steady pace. The scope for significant growth is limited. Vaccine shortages are a major problem which will hinder the growth of the market. The shortage of vaccines affecting some EU/EEA Member States had direct effects on the delivery of national vaccination programmes. Since 2015, nine EU/EEA member states had to adjust their immunization policies.
Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.
What’s covered in the report?
1. Overview of the Europe conjugate vaccine market
2. Market drivers and challenges in the Europe conjugate vaccine market
3. Market trends in the Europe conjugate vaccine market
4. Historical, current and forecasted market size data for Europe based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for Europe based on end user (pediatric and adult conjugate vaccines) – by revenue and by volume
6. Historical, current and forecasted market size data of conjugate vaccines based on countries (EU5, Rest of EU) – by revenue and by volume
7. Historical, current and forecasted market size data for country-wise segments – by revenue and by volume
8. Analysis of the competitive landscape and profiles of major companies operating in the European market
Why buy?
- Understand the demand for conjugate vaccines to determine the viability of the market
- Understand the country-specific market size and observations for each segment
- Develop strategies based on the drivers, trends and highlights for each of the segments
- Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
- Recognize the key competitors of this market and respond accordingly
- Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
- Define the competitive positioning by comparing the products and services with the key players in the market
With the given market data, Netscribes offers customizations according to specific needs.
CHAPTER 1: EXECUTIVE SUMMARY
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary I
1.4 Executive summary II
CHAPTER 2: MARKET OVERVIEW
2.1. Market definitions
2.2. Europe market overview – by revenue
Europe historical (2015-2017) market revenue (USD Bn)
Europe forecasted (2018-2023) market revenue (USD Bn)
Country-wise market (2018-2023) revenue (USD Bn)
2.3. Europe market overview – by volume
Europe historical (2015-2017) market volume (Million units)
Europe forecasted (2018-2023) market volume (Million units)
Country-wise (2018-2023) market volume (Million units)
2.4. Europe market drivers and challenges
2.4.1. Europe market drivers
2.4.2. Europe market challenges
2.5. Europe market trends
2.6. Value chain
2.7.1. Country-specific market overview – EU5
Observation
Key competitors
2.7.1(A) Country-specific market overview – EU5 by revenue and by volume
EU5 historical (2015-2017) market revenue (USD Bn)
EU5 forecasted (2018-2023) market revenue (USD Bn)
EU5 historical (2015-2017) market volume (Million units)
EU5 forecasted (2018-2023) market volume (Million units)
2.7.2. Country-specific market overview – Rest of EU
Observation
Key competitors
2.7.2(A) Country-specific market overview – Rest of EU by revenue and by volume
Rest of EU historical (2015-2017) market revenue (USD Bn)
Rest of EU forecasted (2018-2023) market revenue (USD Bn)
Rest of EU historical (2015-2017) market volume (Million units)
Rest of EU forecasted (2018-2023) market volume (Million units)
CHAPTER 3: EUROPE MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION
3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): Pneumococcal – Europe (USD Bn, Million units)
Market share (2015, 2018 & 2023): Hib – Europe (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): DTP – Europe (USD Bn, Million units)
Market share (2015, 2018 & 2023): Meningococcal – Europe (USD Bn, Million units)
CHAPTER 4: EUROPE MAJOR SEGMENT OVERVIEW BY END USER
4.1. End-user: Pediatric, Adult by revenue, by volume, CAGR
Overview by end-user
Market share (2015, 2018 & 2023): Paediatric – Europe (USD Bn, Million units)
Market share (2015, 2018 & 2023): Adult – Europe (USD Bn, Million units)
CHAPTER 5: EU5 – BY DISEASE INDICATION
5.1. EU5: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.2. EU5: disease indication Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.3. EU5: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.4. EU5: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 6: EU5 – BY END USER
6.1. EU5: end-user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 7: REST OF EU – BY DISEASE INDICATION
7.1. Rest of EU: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.2. Rest of EU: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.3. Rest of EU: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.4. Rest of EU: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 8: REST OF EU – BY END USER
8.1. Rest of EU: end-user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Company market share
Top 5 companies
9.2. Company overview GlaxoSmithKline
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.2(A) Executive profile – GlaxoSmithKline
9.3. Company overview – Pfizer Inc.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.3(A) Executive profile Pfizer Inc.
9.4. Company overview – Merck & Co.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.4(A) Executive profile Merck & Co.
9.5. Company overview – Novartis
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.5(A) Executive profile Novartis
9.6. Company overview – Sanofi Pasteur
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.6(A) Executive profile Sanofi Pasteur
9.7. Company overview – CSL Limited
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.7(A) Executive profile CSL Limited
Appendix
List of tables
Assumptions
Conclusion
Research methodology
About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary I
1.4 Executive summary II
CHAPTER 2: MARKET OVERVIEW
2.1. Market definitions
2.2. Europe market overview – by revenue
Europe historical (2015-2017) market revenue (USD Bn)
Europe forecasted (2018-2023) market revenue (USD Bn)
Country-wise market (2018-2023) revenue (USD Bn)
2.3. Europe market overview – by volume
Europe historical (2015-2017) market volume (Million units)
Europe forecasted (2018-2023) market volume (Million units)
Country-wise (2018-2023) market volume (Million units)
2.4. Europe market drivers and challenges
2.4.1. Europe market drivers
2.4.2. Europe market challenges
2.5. Europe market trends
2.6. Value chain
2.7.1. Country-specific market overview – EU5
Observation
Key competitors
2.7.1(A) Country-specific market overview – EU5 by revenue and by volume
EU5 historical (2015-2017) market revenue (USD Bn)
EU5 forecasted (2018-2023) market revenue (USD Bn)
EU5 historical (2015-2017) market volume (Million units)
EU5 forecasted (2018-2023) market volume (Million units)
2.7.2. Country-specific market overview – Rest of EU
Observation
Key competitors
2.7.2(A) Country-specific market overview – Rest of EU by revenue and by volume
Rest of EU historical (2015-2017) market revenue (USD Bn)
Rest of EU forecasted (2018-2023) market revenue (USD Bn)
Rest of EU historical (2015-2017) market volume (Million units)
Rest of EU forecasted (2018-2023) market volume (Million units)
CHAPTER 3: EUROPE MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION
3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): Pneumococcal – Europe (USD Bn, Million units)
Market share (2015, 2018 & 2023): Hib – Europe (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): DTP – Europe (USD Bn, Million units)
Market share (2015, 2018 & 2023): Meningococcal – Europe (USD Bn, Million units)
CHAPTER 4: EUROPE MAJOR SEGMENT OVERVIEW BY END USER
4.1. End-user: Pediatric, Adult by revenue, by volume, CAGR
Overview by end-user
Market share (2015, 2018 & 2023): Paediatric – Europe (USD Bn, Million units)
Market share (2015, 2018 & 2023): Adult – Europe (USD Bn, Million units)
CHAPTER 5: EU5 – BY DISEASE INDICATION
5.1. EU5: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.2. EU5: disease indication Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.3. EU5: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.4. EU5: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 6: EU5 – BY END USER
6.1. EU5: end-user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 7: REST OF EU – BY DISEASE INDICATION
7.1. Rest of EU: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.2. Rest of EU: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.3. Rest of EU: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.4. Rest of EU: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 8: REST OF EU – BY END USER
8.1. Rest of EU: end-user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Company market share
Top 5 companies
9.2. Company overview GlaxoSmithKline
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.2(A) Executive profile – GlaxoSmithKline
9.3. Company overview – Pfizer Inc.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.3(A) Executive profile Pfizer Inc.
9.4. Company overview – Merck & Co.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.4(A) Executive profile Merck & Co.
9.5. Company overview – Novartis
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.5(A) Executive profile Novartis
9.6. Company overview – Sanofi Pasteur
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.6(A) Executive profile Sanofi Pasteur
9.7. Company overview – CSL Limited
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
9.7(A) Executive profile CSL Limited
Appendix
List of tables
Assumptions
Conclusion
Research methodology
About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research
